Category: ACN Newswire

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.From a clinical value perspective，VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.“UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”“Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”“Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.Industry observers widely expect VELSIPITY(R) to become Everest's next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest's revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月6日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀今日宣佈，中國國家藥品監督管理局（NMPA）已批准維適平(R)（精氨酸艾曲莫德片, VELSIPITY(R)）的新藥上市許可申請（NDA），用於治療對傳統治療或生物制劑應答不充分、失應答或不耐受的中度至重度活動性潰瘍性結腸炎成人患者。潰瘍性結腸炎是一種病因尚不明確、易復發的慢性腸道炎症性疾病。近年來，中國潰瘍性結腸炎發病率持續上升，並呈現年輕化趨勢，預計患者人數將由2025年的約98萬增長至2031年的約150萬。疾病對患者生活質量帶來長期負擔，臨床亟需實現更加穩定、持久的疾病控制。作為新一代高選擇性S1P受體調節劑，維適平(R)每日一次口服，可實現快速起效和強效深度黏膜愈合，並具有良好的安全性特征，具備最佳藥物（best-in-disease）潛質，為成人潰瘍性結腸炎患者提供新的一線治療選擇。據悉，維適平(R)此次獲批，是基於亞洲多中心III期注冊臨床ENLIGHT UC研究（ES101002）的結果和全球III期注冊研究ELEVATE UC（包括ELEVATE UC 52和ELEVATE UC 12研究）的結果。ENLIGHT UC研究是迄今完成的最大規模亞洲中重度活動性潰瘍性結腸炎患者的III期注冊臨床研究，總計納入340名患者。結果顯示，維適平(R)治療組在所有主要和次要療效終點上均達到統計學顯著性與臨床意義，且安全性良好。研究結果已發表於國際頂級學術期刊柳葉刀子刊《The Lancet Gastroenterology & Hepatology》。從臨床價值來看，維適平(R)憑借每日一次口服的治療方案，能夠快速起效並達到臨床緩解，同時還在黏膜愈合和組織學改善等方面療效顯著，同時安全性良好。對此，中華醫學會消化病學分會前任主任委員、炎症性腸病學組組長、中山大學附屬第一醫院消化內科學術帶頭人、首席專家陳旻湖教授指出，我國目前正處於潰瘍性結腸炎發病率和患病率快速上升階段，該疾病常反復發作，嚴重影響患者生活質量，對個人、家庭和醫療資源造成沉重負擔。實現黏膜愈合有助於更有效地控制症狀，降低復發風險，改善患者生活質量。黏膜愈合是國內外臨床指南公認的潰瘍性結腸炎治療目標，這不僅關系到疾病的長期症狀緩解，也與改善患者生活質量密切相關。維適平(R)亞太臨床試驗牽頭研究者、世界胃腸病組織執委兼司庫、亞太地區消化病學會副主席、中華醫學會消化病學分會第十、十一屆副主委、空軍軍醫大學西京消化病醫院吳開春教授指出，長期以來，我國潰瘍性結腸炎治療面臨傳統療法療效有限、給藥便捷性差以及不良反應多等諸多局限。已獲批的生物制劑和小分子治療也存在「療效天花板」及「失應答」等問題。維適平(R)通過調控淋巴細胞遷移，從源頭控制腸道炎症，並促進黏膜愈合。在多個臨床研究中維適平(R)展現出顯著療效，尤其在快速起效、實現無激素緩解及深度黏膜愈合方面具有明顯臨床優勢。此次獲批標志著維適平(R)從臨床研究到上市的完整驗證，為患者提供創新治療選擇，並推動中重度潰瘍性結腸炎管理進入新階段。雲頂新耀董事會主席吳以芳表示：「自身免疫性疾病在全球範圍內對患者造成長期而深遠的影響，在中國乃至全球範圍內，仍存在大量尚未滿足的臨床需求。維適平(R)的獲批不僅體現了創新療法在潰瘍性結腸炎治療中的臨床價值，也彰顯了公司堅持以國際研發標准推進創新藥物發展的長期戰略。我們期待通過持續拓展全球化佈局，讓更多患者受益於高質量、具有突破性的治療選擇。」雲頂新耀首席執行官羅永慶表示: 「此次維適平(R)在中國的獲批，填補了中重度潰瘍性結腸炎治療領域的重要空白，並為以深度黏膜愈合為目標的創新口服治療提供了新的選擇。公司將加快推進維適平(R)的商業化進程，並積極推動納入國家醫保目錄，持續提升創新療法在中國的可及性和可負擔性，讓更多患者受益。」值得一提的是，維適平(R)的臨床價值已獲得多項國際權威指南的充分認可，被先後納入2024年美國胃腸病協會（AGA）臨床實踐指南及2025年美國胃腸病學院（ACG）臨床指南，並獲強烈推薦。此前，該藥已於2024年和2025年被列入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄（文件中名稱為「伊曲莫德」）。目前，維適平(R)已在美國、歐盟以及中國大陸、中國香港、中國澳門、新加坡等多個國家和地區獲得新藥上市批准。2025年3月，雲頂新耀啟動維適平(R)嘉善工廠建設項目，為本地化生產及長期可及性提供有力支持。維適平(R)的成功獲批，進一步夯實了雲頂新耀在自身免疫疾病領域的產品佈局，也是公司2030年發展戰略的重要組成部分。該戰略以「BD合作 + 自主研發」雙輪驅動為核心，致力於通過商業化實現確定性價值，同時通過持續創新研發構建長期成長動能，推動管線的延續性與可持續發展。在商業化平台建設上，雲頂新耀已佈局三款商業化產品，並著力建立全渠道商業化體系及藥品全生命周期商業化能力。計劃到2028年實現收入規模超過100億元人民幣，而到2030年收入規模超過150億元人民幣（其中現有管線銷售收入約90億元人民幣而新引進管線銷售收入約60億元人民幣）；收入的年複合增長率預計在2025至2030年超過50%，2030年後保持超過15%。同時，商業化產品數量將提升至20款以上，包括耐賦康(R)、維適平(R)、依嘉(R)、樂瑞泊(R)（萊達西貝普）及MT1013等。業內普遍認為，維適平(R)有望成長為雲頂新耀又一重磅產品，其銷售峰值預計可達50億元人民幣。隨著維適平(R)商業化進程的持續推進，公司整體收入結構與成長曲線有望進一步優化。未來，雲頂新耀將繼續聚焦重大未滿足臨床需求，持續強化差異化創新管線，加速推進具有國際競爭力的創新療法落地，助力公司實現可持續成長，並為患者與社會創造更大的健康價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Eternal Beauty Holdings Limited (“Eternal Beauty” or the “Group”) (Stock Code: 6883.HK), a pioneer in China’s beauty and fragrance industry, announced its first-ever collaboration with Lane Crawford, a premier luxury department store, to launch an exclusive boutique niche fragrance section at its Harbour City store in Tsim Sha Tsui. The collaboration aims to further advances the Group’s strategy focused on high-margin niche fragrance brands, strengthens its premium brand footprint through an elite retail network, and captures the growing profit opportunities in the niche fragrance for Chinese Mainland and Hong Kong markets.The zone brings together four international niche fragrance brands under the immersive concept of a "Luxury Niche Perfume Street" with European flair, featuring Atkinsons, Clive Christian, Memo Paris and SOLFÉRINO, each presented with its unique style and heritage. Clive Christian and SOLFÉRINO are making their debut in Hong Kong, offering a rare experience to local high-end consumers. By leveraging Lane Crawford’s premium retail network that reaches high-spending customers, the Group effectively enhances brand penetration in the Hong Kong market. This initiative successfully introduces the Group’s portfolio into a core upscale retail destination in Hong Kong, demonstrating the Group’s strengths in channel expansion and retail curation, while further solidifying its brand influence and long-term growth momentum in the niche fragrance portfolio.Brand Introduction:AtkinsonsThe 200-year-old British "Royal Fragrance House" reinvents the rebellion and elegance of 19th-century English gentlemen, transforming historical formulas into a modern, contemporary aura.Clive ChristianThe first exclusive collectors’ boutique in Hong Kong: Clive Christian is a luxury British perfume house that creates the world's finest perfumes. A legacy of British craftsmanship, unparalleled quality in concentration and complexity, unashamedly indulgent and luxurious presentation.Memo ParisMemo Paris is a Parisian fragrance house, see each fragrance as a travel note captured in scent. Preserve memory of a journey to unique destination. Memo Paris sketches a delicate, emotional map of the world: a universe where memories become scents.SOLFÉRINODebuting brilliantly in Hong Kong, SOLFÉRINO is born in Paris, France, the brand draws inspiration from the historic architecture of this City of Lights, showcases French elegance with exceptional craftsmanship and presenting Parisian audacity and creativity.Ms. Wendy Lau, Executive Director of Eternal Beauty and Chairman of the International Fragrance Association, said, “With over 40 years of industry experience, Eternal Beauty has cultivated sharp market vision, distinctive taste, and profound expertise. This enables the Group to accurately identify and introduce brands that align with market trends and carry strong profit potential into the Greater China market, which continues to demonstrate vigorous consumption upgrade momentum. We are thrilled to partner with Lane Crawford, an influential luxury department platform in Asia, to create this exclusive boutique niche fragrance section in Hong Kong’s core luxury shopping district, leveraging the Group’s strengths in niche fragrance brand management and retail channel development. This is not only an important step for the Group to deepen the niche fragrance market, but also a concrete manifestation of our niche fragrance brand expansion strategy. Moving forward, the Group will continue to explore collaborations with top-tier retail partners. By introducing more niche brands with high growth potential, it will strengthen its long-term growth momentum and enhance sustainable profitability in the fragrance market.”Hong Kong's fragrance market continues to benefit from the momentum of the emotional economy, demonstrating relatively resilient growth against the backdrop of a steady recovery in the overall retail sector. In December 2025, the value of total retail sales in Hong Kong increased by 6.6% YoY; according to market’s outlook reports, the total retail sales in Hong Kong are expected to grow by nearly 8% in 2026, reaching approximately HKD 410 billion, indicating a continued recovery in local consumer demand. Ms. Chole Lam, Executive Director and Chief Executive Officer of Eternal Beauty, said, “In recent years, experiential retail and emotional consumption have gradually emerged as new retail trends, with emotional value playing an increasingly significant role in consumer decision-making. The ability to establish emotional resonance with consumers is becoming an important direction for brand expansion and product innovation. Emerging consumption segments, represented by high-end and niche fragrances, are more being regarded as categories that carry emotional value and lifestyle propositions, highlighting their growth potential in the retail recovery process.”Eternal Beauty has established an omni sales channel network over 400 cities across Chinese Mainland, Hong Kong and Macau. The cooperation with Lane Crawford is an important part of the Group’s retail channel strategy, aiming to enhance the consumer experience and sales conversion by leveraging the prime location and high customer traffic of the premium department store.Photo CaptionEternal Beauty and Lane Crawford debut landmark niche fragrance zone, bringing together four international niche fragrance brands under the concept of a "Luxury Niche Perfume Street". The zone immersively showcasing four distinctive and heritage-rich brands: Atkinsons, Clive Christian, Memo Paris, and SOLFÉRINO.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharingAbout Eternal Beauty Holdings LimitedEternal Beauty Holdings Limited is the largest perfume group (apart from brand-owner perfume groups) in China (including Hong Kong and Macau) in terms of retail sales in 2023. It primarily sells and distributes products procured from third-party brand licensors, and deploys market for these brand licensors, offering such services as brand management, and designing and implementing customized market entry and expansion plans for their brands. The Group boasts large and diversified brand portfolios that include not only perfumes, but also color cosmetics, skincare products, personal care products, eyewear and home fragrances. As at 30 September 2025, it conducted product distribution and market deployment for a total of 74 external brands, including Hermès, Van Cleef & Arpels, Chopard, Albion and Laura Mercier, with products in different pricing tiers and of versatile features that meet the differentiated demands of consumers in Chinese Mainland, Hong Kong and/or Macau. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月6日 - (亞太商訊 via SeaPRwire.com) - 中國香水產業領航者穎通控股有限公司（「穎通控股」或「集團」）（股份代號：6883.HK）宣佈與頂級奢侈品百貨連卡佛達成首度合作，於尖沙咀海運大廈連卡佛內設立首個小眾香水限定專區，進一步落實集團聚焦高毛利小眾香水品牌的發展策略，並透過頂級零售網絡深化高端品牌佈局，把握中國內地及香港高端香氛市場持續增長所帶來的盈利機遇。專區雲集四大國際高端香氛品牌，以充滿歐洲風情的「高級小眾香水街」為概念，沉浸式呈現 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四個各具風格與傳承的品牌。Clive Christian 及 SOLFÉRINO 更是首度登陸香港，為本地高端消費者帶來獨家體驗，並藉助連卡佛覆蓋高消費客群的優質零售網絡，有效提升品牌在香港市場的滲透率，進一步將集團旗下品牌引入香港核心高端零售據點，展現集團在渠道拓展與零售策展方面的實力，鞏固於高端香氛市場的品牌影響力及長期增長動能。品牌介紹：Atkinsons擁有二百年歷史來自英國的「皇室御用香氛品牌」，重塑十九世紀英倫紳士的叛逆與優雅，將歷史配方化為現代摩登氣息。Clive Christian香港首間典藏級專櫃：源自英國倫敦的 Clive Christian 被譽為「世界最奢華的香水之一」，致敬英國皇室貴族經典與頂級奢華工藝傳承，彰顯無可比擬永恆優雅的底蘊。Memo Paris來自法國的 Memo Paris 以旅行與記憶為靈感，以香氣銘記旅途故事，繪製一幅詩情畫意的香氛情感地圖，將世界景致匯聚於瓶中。SOLFÉRINO首次於香港耀目登場的 SOLFÉRINO 誕生於法國巴黎，靈感源自這座光之城的歷史建築，以精湛工藝詮釋法式優雅，創作前衛而富創意的香氣。穎通控股執行董事及國際香氛協會主席劉頴賢女士表示：「憑藉四十餘年的行業經驗，穎通積累了敏銳視野、獨到品味與深厚專業知識，得以精準甄選契合市場趨勢且具備盈利潛力的品牌，並引入蘊藏巨大消費升級動能的大中華市場。我們很高興與亞洲具影響力的奢侈品百貨連卡佛攜手，在香港核心奢侈品商圈打造首個小眾香水專區，充分發揮穎通在高端香氛品牌運營與零售渠道佈局方面的專長。這不僅是集團深化小眾香水市場的重要一步，更是我們高端香氛品牌佈局策略的具體實踐。未來，集團將持續探索與頂級零售夥伴的合作機會，引入更多具高成長潛力的小眾品牌，進一步強化集團在高端香氛市場的長期增長動能與可持續盈利能力。」香港香氛市場持續受惠於情緒經濟帶動，在整體零售業穩步復甦的環境下，展現出相對強韌的增長勢頭。2025年12月，香港零售業總銷貨價值按年上升6.6%；而根據市場展望報告預測，2026年香港零售總額有望增長近8%，達到約4,100億港元，顯示本地消費需求正持續回暖。穎通控股執行董事兼首席執行官林荊女士表示：「近年，體驗式零售和情緒消費漸成為零售新潮流，情緒價值在消費決策中的比重明顯提升，能否與消費者建立情緒共鳴，正日益成為品牌拓展與產品創新的重要方向。以高端與小眾香氛為代表的新興消費板塊，愈來愈多地被視為承載情緒價值與生活方式主張的品類，顯示其在零售復蘇進程中的增長潛力。」穎通控股已建立覆蓋中國內地、香港及澳門逾400個城市的全渠道銷售網絡，是次與連卡佛的合作為集團零售渠道升級策略的重要一環，旨在透過高端百貨的黃金地段與客流量，提升品牌消費體驗與銷售轉化。圖片說明穎通控股與連卡佛合作開設首個小眾香水專區，雲集四大國際高端香氛品牌，以充滿歐洲風情的「高級小眾香水街」為概念，沉浸式呈現 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四個各具風格與傳承的品牌。請通過此鏈接下載更多高清圖片：https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharing關於穎通控股有限公司穎通控股有限公司是中國（包括香港及澳門）最大的香水集團（除品牌所有者香水集團外，按2023年零售額計），主要從事銷售及分銷從第三方品牌授權商採購的產品及為該等品牌授權商進行市場部署，例如為其品牌設計及實施定制的市場進入及擴張計劃。穎通控股擁有龐大且多元化的品牌組合，不僅包括香水，還包括彩妝、護膚品、個人護理產品、眼鏡及家居香氛。截至2025年9月30日，穎通控股為合共74個外部品牌進行產品分銷及市場部署，包括 Hermès、Van Cleef & Arpels、Chopard、Albion及Laura Mercier，涵蓋多元化的定價層次及功能，迎合中國內地、香港及或澳門消費者的差異化需求。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月6日 - (亞太商訊 via SeaPRwire.com) - 2月4日至5日，中國再保召開2026年黨建和經營管理工作會議。會議以習近平新時代中國特色社會主義思想為指導，深入學習貫徹黨的二十大和二十屆歷次全會、中央經濟工作會議、中央金融工作會議、二十屆中央紀委五次全會精神，落實上級單位和監管部門管理要求，總結2025年工作，回顧「十四五」發展成效，深入分析當前形勢和任務，部署2026年重點工作。中國再保黨委書記、董事長莊乾志出席會議並講話，黨委副書記、副董事長、擬任總裁朱曉雲作經營管理工作報告，紀委書記李丙泉作紀檢工作報告，黨委副書記朱海林主持會議並作總結講話。財政部、國家金融監管總局、中投公司代表到會指導。高質量發展再上新台階會議指出，2025年，中國再保堅持以黨的政治建設為統領，全面加強黨的作風建設，深入貫徹中央八項規定精神學習教育取得實效。堅持金融工作的政治性、人民性，服務國家戰略風險保額超87.5萬億元，同比增長11.4%。聚焦主責主業持續深化改革創新，圓滿完成中再巨災公司增資，經營質效顯著提升，被認定為我國境內首家「國際活躍保險集團」。會議指出，「十四五」以來，中國再保以黨建「領航工程」聚力鑄魂，「世界一流」戰略願景振奮人心，經營理念重塑成效顯著，「一體兩翼」格局拓寬空間，數字化轉型穩步推進，國際化發展實現突破，承保利潤大幅改善，所有國際業務平臺均實現承保盈利，國際業務經營業績向穩向優，為「十五五」新征程打下良好基礎。譜寫「十五五」發展嶄新篇章會議指出，未來十年是我國保險業補缺口、實現高質量發展的關鍵時期。中國再保要以黨的政治建設為統領，緊扣金融工作主線，發揮保險再保險經濟「減震器」和社會「穩定器」功能，加快推進業務模式轉型和管理機制優化，加快提升專業能力，做到「五個堅持」和「五個突破」，在建設金融強國的偉大事業中堅定扛起中國再保的光榮使命。做到「五個堅持」，一是堅持2035年建成「世界一流」不動搖，錨定願景目標不放鬆。二是堅持穩中求進工作總基調，整體工作穩字當頭，具體工作以進促穩。三是堅持正確的經營觀、業績觀、風險觀，長期堅持「發展有規模、承保增效益、投資要穩健」的經營理念。四是堅持聚焦主責主業和發揮功能作用，積極主動融入中國金融改革發展大局。五是堅持高質量發展和高水平安全的有機統一，守牢風險防控底線。實現「五個突破」，一是業務轉型突破，攻堅克難，謀劃好再保險轉型發展路線圖、直接保險高質量發展路線圖、保險科技創新發展路線圖。二是治理結構突破，強化集團管控，完善治理機制，做到既「放得活」，又「管得好」。三是激勵約束突破，將「要我突破」轉變為「我要突破」，實現激勵有效、約束有力。四是國際化能力突破，打造國際化專業人才隊伍及境外機構管理團隊。五是企業文化塑造突破，追求專業盡責卓越工作目標，弘揚簡單、高效、務實、合規工作作風。會議強調，「十五五」期間，中國再保要堅持和加強黨的全面領導，以高質量黨建引領高質量發展；要志在一流，以自身高質量發展的確定性應對外部環境的不確定性；要增強大局觀念，自覺把工作融入黨和國家事業大局、世界一流建設新征程中謀劃推進；要勇於擔當，做行動派、實幹家，既真幹又會幹，用扎實奮鬥創造經得起實踐和歷史檢驗的工作業績。部署2026年重點工作會議明確，2026年，中國再保要堅持以習近平新時代中國特色社會主義思想為指導，深入貫徹黨中央決策部署，堅持用改革精神和嚴的標準管黨治企，擔當作為、攻堅克難，重點做好七方面工作。一是始終將黨的政治建設擺在首位，樹立正確的政績觀，扎實做好金融「五篇大文章」，提升各級幹部政治能力。二是深入貫徹新時代黨的組織路線，為集團高質量發展提供強有力幹部人才支撐。三是扎實開展「黨建效能提升年」，實現「兩個功能」融入中心工作的效能明顯提升。四是高質量編制「十五五」規劃，做好戰略任務分解落地。五是全面深化改革創新，增強高質量發展動能，強化集團管控引領，調動子公司經營管理主動性、積極性，進一步提升國際化、數字化發展水平。六是認真貫徹落實自我革命「五個進一步到位」重要要求，以更高標準更實舉措推進全面從嚴治黨。七是積極建設中再特色企業文化，為世界一流建設凝聚發展合力。會議要求，2026年集團系統經營管理工作要堅決貫徹「發展有規模、承保增效益、投資要穩健」的經營理念，以改革求突破、以轉型促發展、以創新增動能、以管理提質效，守穩築牢風險防線，不斷增強經營發展韌性，奮力實現「十五五」良好開局，譜寫高質量發展新篇章。同時，會議對各子公司經營要求進行具體部署。集團系統要堅持再保特色優勢，著力服務國家戰略；堅持總部統籌引領，著力強化穿透管理；堅持業務驅動導向，著力加快數字化轉型；堅持境外管控優化，著力提升國際競爭力；堅持築牢底線思維，著力強化全面風險管理。會議強調，中國再保要以更高標準、更實舉措推進全面從嚴治黨，把深入落實「從嚴監督執紀要進一步到位」作為貫穿全年的主題主線，強化政治監督，深化正風肅紀，一體推進不敢腐、不能腐、不想腐，持續開展「紀檢工作規範化法治化正規化建設年」行動，推進新時代新征程紀檢工作高質量發展，為集團公司「十五五」開好局起好步提供堅強保障。集團公司黨委、董事會、總裁室成員，各子公司班子成員、分/子公司及部門主要負責人，海外經營機構負責人，集團公司部門和處室負責人，老幹部代表等現場參會。集團系統其他相關人員通過視頻方式參會。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 根據香港聯交所披露的文件，新加坡政府投資公司（GIC Private Limited）入股歌禮製藥，以每股均價12.18港元，買入64,128,000股普通股股份，合計涉資約7.81億港元，折合約1億美元。入股完成後，GIC持有歌禮製藥64,128,000股股份，占公司已發行股本約6.42%，正式躋身公司主要機構股東行列。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 由香港貿易發展局（香港貿發局）主辦的全球最大一站式珠寶商貿平台，將於3月初以「兩展兩地」的成功模式揭幕。第12屆香港國際鑽石、寶石及珍珠展於3月2至6日在亞洲國際博覽館舉行，展出各類珠寶原材料。第42屆香港國際珠寶展則於3月4至8日假灣仔香港會議展覽中心舉辦，展示各款珠寶首飾成品。香港貿發局副總裁古靜敏表示：「今屆珠寶雙展將雲集逾40個國家及地區、約4,000家展商，當中七成來自香港以外的地區，其中巴西、阿聯酋和印度展商更擴大參展規模，而烏茲別克更是首次參展。香港貿發局積極打造全球最大一站式珠寶商貿平台，凸顯香港作為國際商貿及珠寶採購中心的地位。」回顧環球珠寶市場，2025年本港貴重珠寶出口至東盟錄得51%升幅，而出口至英國、澳洲及瑞士的增長分別按年上升36%、28%及10%。兩展雲集逾40個展團 硬足金展館開啟金飾新篇章珠寶雙展一直備受環球業界支持，今年雲集超過40個展團，當中包括中國內地、台灣、印度、以色列、韓國、緬甸、新加坡、斯里蘭卡、泰國、烏茲別克、比利時、德國、意大利、西班牙、土耳其、巴西、哥倫比亞、墨西哥及美國等。世界黃金協會將首設硬足金展館，合共11家中國內地展商，向國際市場展示嶄新黃金技藝，目標以展會作「出海」平台，開拓環球商機。此外，今年香港表廠商會首次組團參展，來自湖北的竹山綠松石展團也首度亮相。而坦桑石協會、彩色寶石協會、亞太區創作師協會及亞洲珠寶文化設計工藝協會亦將繼續參展，香港珠寶玉石廠商會將聯同Italian Exhibition Group（IEG）再度設館，展示製造珠寶的最新設備和技術。國際品牌 矚目登場香港國際珠寶展的「品牌精粹廊」展區（Hall of Fame）載譽歸來，規模較去年增加逾四成，匯聚更多國際知名珠寶品牌；其中土耳其領先鑽石珠寶品牌 Zen Diamond（展位：CEC 3B-C12）將帶來採用精細裁切工藝的鑽戒系列。於「珠寶精粹廊」展區（Hall of Extraordinary），香港展商恒和鑽石（展位：CEC GH-C07）則展出一枚18K白金及玫瑰金鑲嵌藍鑽與淺彩粉鑽戒指。 另一香港展商Unique Brilliant Limited（展位：CEC GH-C13）將展示一套項鏈與耳環組合，紅寶石未經加熱處理，呈現珍稀的「鴿血紅」（pigeon blood red）色澤。東方美學展現非遺工藝今年展會雲集多款承載東方文化的珠寶。來自中國內地的廣東嘉寶閣傳世珠寶（展位：CEC GH-A16），帶來以國家級非遺工藝「花絲鑲金」，以人手製作的蝴蝶胸針，耗時逾四個月。另一內地展商賽菲爾珠寶（展位：CEC 3E-E02）則帶來了「宮廷新中式」風格的作品，運用六項古法黃金工藝製作而成，將傳統技藝展現在當代首飾上。內地近年興起硬足金技術，高純度和高硬度的特性，令金飾可以融入更多時尚和現代設計元素。由世界黃金協會舉辦的研討會將分析最新的黃金市場情況和硬足金技術。展會期間將舉行多場關於東方美學珠寶的活動。香港珠寶首飾業商會主辦的香港國際時尚足金飾設計比賽，鼓勵設計師創作出迎合東盟及中東年輕市場，兼具文化內涵和商業潛力的金飾作品，頒獎典禮將於展會期間舉行。由香港玉器商會主辦，首屆國際翡翠玉器首飾設計大賽2026亦會在展會期間舉行頒獎典禮。創意設計領潮流緊貼潮流及具創意的產品有助業界突圍而出。有展商將創新構思化成潮流產品，Austy Lee Company Limited（展位：CEC 1E-F32）趁馬年將至，推出以斑馬紋理為設計靈感的手鐲。今年「珠寶設計精選」展區（Designer Galleria）迎來新展商Zheng Hong Collective（展位：CEC 1CON-067A），帶來一款飛魚胸針，佩戴時翅膀和尾端會隨身體而擺動。今年香港珠寶設計比賽以「未琢之韻．自然之美」為題，啟發本地學生及業界精英以作品演繹大自然之美與設計故事，凸顯珠寶設計的多元面貌，大會將於展會期間公佈賽果。稀世瑰寶閃耀雙展兩展一直為買家網羅古典珍藏及稀有珠寶，香港國際珠寶展的香港展商拾璣古董珠寶（展位：CEC CH-F13）展出20 世紀、70 年代製作的布契拉提粉色藍寶石套裝。另有展商 World Coins Co., Ltd. （展位：CEC CH-N12）帶來19世紀意大利工匠的雙色琺琅鑽石首飾，首飾連同原盒完整保存至今超過100年。香港國際鑽石、寶石及珍珠展則有德國展商Caram e.K. （展位：AWE 8-F05）帶來18.98卡AGL認證、收藏級的天然粉紅藍寶石；加大拿展商Korite Ammolite Ltd（展位：AWE 8-F35）展示18K金AA級斑彩石配鑽石頸鍊。活動方面，香港國際珠寶展將舉行「珠寶風格從何而來？探究時代與工藝的印記」座談會，特別邀請英國著名歷史學家及珠寶權威 Dr. Jack Ogden主講，深入剖析珠寶工藝演進及時代審美變遷。逾20場論壇活動 探討AI及網絡營銷等業界熱話珠寶雙展期間將舉行超過20 場行業講座與交流活動，涵蓋行業趨勢、網絡營銷和珠寶科技等，其中香港國際珠寶展第二日將剖析人工智能如何由設計走到商業化，推動珠寶行業發展。另外大會將安排研討會，網紅分享如何利用電商平台提高珠寶品牌的影響力、增加銷售和實踐經驗等，讓業界加快打通線上線下的協同合作渠道。體驗與服務並重 全球買家首選平台展覽吸引環球大型珠寶零售連鎖店、高端、輕奢及設計師珠寶品牌到場採購，為買賣雙方締造商機，並推動業界交流。此外，香港貿發局為持續優化世界各地買家來港採購的體驗，聯同香港旅遊發展局及多家企業推出買家專屬優惠，涵蓋餐飲、機票、酒店等，讓參觀珠寶雙展的買家，同時感受香港獨有魅力。大會將安排免費穿梭巴士，接載買家往返亞洲國際博覽館及市區（包括灣仔香港會議展覽中心），詳情請參閱展會網站。線上線下相結合 便利入場洽商採購今年珠寶雙展將沿用「展覽+」（EXHIBITION+）線上線下融合模式，除了在展會現場採購，由2月23日至3月13日，「商對易」(Click2Match）的人工智能會為展商及買家提供線上商貿配對。在場買家則可利用「掃碼易」（Scan2Match）掃描展商的二維碼，於展會期間或之後隨時隨地於線上洽談。在買家入場方面，「香港貿發局商貿平台」流動應用程式（HKTDC Marketplace App）及兩展的官方網頁都提供網上驗證功能。買家只需透過上述平台登記、上傳照片和有效證件，即可獲取已驗證的買家證，無需現場排隊登記或驗證，大大提升採購效率。圖片下載︰https://bit.ly/4ayrcAo香港貿發局副總裁古靜敏（中）、香港貿發局珠寶業諮詢委員會主席周允成（左）以及香港貿發局香港國際珠寶展及香港貿發局香港國際鑽石、寶石及珍珠展籌備委員會主席黃紹基（右），出席今天（2月5日）舉行的香港國際珠寶展和香港國際鑽石、寶石及珍珠展新聞發佈會。古靜敏（前排左三）連同一眾香港貿發局香港國際珠寶展及香港國際鑽石、寶石及珍珠展籌備委員會委員，以及表演嘉賓合照。藝人陳曉華（右三）率領一眾模特兒演繹各款瑰麗珠寶。藝人陳曉華佩戴展商安東公司帶來的天然緬甸翡翠套裝，碧綠晶瑩的翡翠鑽石頸鏈、戒指及耳環，設計高貴優雅。鳳凰常見於中式婚嫁飾品，象徵吉祥、如意，展商老鳳祥帶來富有中式魅力的國潮婚嫁系列，打造女性宮廷般尊貴的飾品。相關網頁 香港國際珠寶展展覽網頁http://hkjewelleryshow.hktdc.com/tc兩展穿梭巴士安排https://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcec展會活動https://www.hktdc.com/event/hkjewellery/tc/intelligence-hub 香港國際鑽石、寶石及珍珠展展覽網頁http://hkdgp.hktdc.com/tc兩展穿梭巴士安排https://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-awe展會活動https://www.hktdc.com/event/hkdgp/tc/intelligence-hub香港貿發局新聞中心：http://mediaroom.hktdc.com/tc傳媒查詢香港貿易發展局傳訊及公共事務部：簡惠宜電話：(852) 2584 4055電郵：winnie.wy.kan@hktdc.org黃家欣電話：(852) 2584 4524電郵：katy.ky.wong@hktdc.org張敏萱電話：(852) 2584 4137電郵：jane.mh.cheung@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構，負責促進、協助和發展香港貿易。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one-stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld-Expo and will feature a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre and will showcase finished jewellery pieces.Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with 70% coming from outside Hong Kong. Exhibitor participation from Brazil, United Arab Emirates and India has expanded, and Uzbekistan joins for the first time. The HKTDC presents the world’s largest one-stop jewellery marketplace to highlight Hong Kong’s status as an international trade capital and jewellery sourcing hub.”In reviewing the global jewellery market, Hong Kong’s export volume of premium jewellery to ASEAN recorded a 51% increase, while exports to the United Kingdom, Australia and Switzerland grew year-on-year by 36%, 28% and 10% respectively.Over 40 themed pavilions, including a new Hard Pure Gold PavilionThe twin shows attract strong global industry support, with exhibitors participating from over 40 regional and industry pavilions. Participating regions include Chinese Mainland, Taiwan, India, Israel, Korea, Myanmar, Singapore, Sri Lanka, Thailand, Uzbekistan, Belgium, Germany, Italy, Spain, Türkiye, Brazil, Colombia, Mexico and the United States, etc.The World Gold Council debuts the Hard Pure Gold Pavilion, featuring a total of 11 exhibitors from Chinese Mainland, showcasing innovative gold craftsmanship to the global market. The pavilion aims to leverage the fairs as a springboard for international expansion.The Hong Kong Watch Manufacturers Association Ltd will participate as a pavilion for the first time, while the Zhushan Turquoise pavilion from Hubei will also make its debut. Other returning participants include the Tanzanite Foundation, the International Colored Gemstone Association (ICA), the Asia Pacific Creator Association, and the Asia Jewellery Culture Design and Crafts Association. The Hong Kong Jewellery & Jade Manufacturers Association will once again join forces with the Italian Exhibition Group (IEG) to present advanced jewellery manufacturing equipment and technologies.International brands in the spotlightThe Hall of Fame at the Hong Kong International Jewellery Show makes a highly anticipated return this year with more than 40% expansion in scale. It will welcome renowned international jewellery brands and help enhance global brand exposure. Turkish diamond jewellery brand Zen Diamond (Booth: CEC 3B-C12) presents diamond ring collections featuring exquisite cutting techniques. At the Hall of Extraordinary, Hong Kong exhibitor Continental Diamond Company (Booth: CEC GH-C07) showcases an 18K white and rose gold ring set with blue and light pink diamonds. Another Hong Kong exhibitor, Unique Brilliant Ltd (Booth: CEC GH-C13), unveils a necklace and earring set, the rubies display the coveted “pigeon blood red” colour.Oriental Aesthetics showcases cultural heritage craftsmanshipThis year’s shows will feature numerous jewellery pieces inspired by Asian culture and heritage. Chinese Mainland exhibitor, Guangdong JIABAO Pavilion Jewellery (Hong Kong) Company Ltd (Booth: CEC GH-A16) presents an 18K gold, handmade filigree butterfly brooch, made with national intangible heritage craft, with each piece taking over four months to complete. Another Chinese Mainland exhibitor, Shenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02), brings a “Palatial Modern Chinese Style” jewellery series incorporating six traditional gold techniques, blending heritage craftsmanship with modern jewellery design.In recent years, hard pure gold technology has gained strong momentum in Chinese Mainland. Its high purity and enhanced hardness enable lighter, more durable designs with modern aesthetics. A seminar organised by the World Gold Council will examine the latest developments in the global gold market and hard pure gold technology.During the fairs, a series of events spotlighting Oriental aesthetics in jewellery will be staged. Hong Kong International Fashion Chuk Kam Jewellery Design Competition 2026, organised by the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, encourages designers to create commercially viable and culturally rich gold jewellery for young consumer markets in ASEAN and the Middle East. Its award presentation ceremony will be held during the fairs.In addition, the inaugural International Fei Cui Jewellery Design Competition 2026, organised by the Hong Kong Jade Association, will also host its awards presentation during the fairs.Creative design sets the trendInnovative and trend-driven products help the industry stand out. Austy Lee Company Ltd (Booth: CEC 1E-F32) introduces bangles inspired by zebra patterns for the Year of the Horse. Designer Galleria welcomes new exhibitor Zheng Hong Collective (Booth: CEC 1CON-067A), featuring a brooch whose movable wings and tail sway with the wearer.The 27th Hong Kong Jewellery Design Competition, themed “Pure Elegance – Natural Beauty”, returns to nurture creative talent. Local students and industry professionals interpret the beauty of nature and their design stories through their creations, highlighting the diverse facets of jewellery design. Winning designs will be announced during the fairs.Rare treasures dazzle across both showsAs always, the twin shows offer buyers an outstanding selection of antique and rare jewellery. At the Hong Kong International Jewellery Show, Hong Kong exhibitor Baroque Antique & Jewellery Limited (Booth: CEC CH-F13) presents a 1970s Buccellati pink sapphire suite, while World Coins Co., Ltd. (Booth: CEC CH-N12) showcases a 19th-century Italian bi-colour enamel diamond piece preserved in its original box for over 100 years. At the Hong Kong International Diamond, Gem & Pearl Show, German exhibitor Caram e.K. (Booth: AWE 8-F05) features an 18.98-carat AGL-certified natural pink sapphire, while Canadian exhibitor Korite Ammolite Ltd. (Booth: AWE 8-F35) displays an 18K gold AA-grade ammolite and diamond necklace.The Hong Kong International Jewellery Show will also host a seminar titled “The Origins of Style: Tracing the Imprint of Time and Craftsmanship.” This seminar will invite British historian and jewellery authority Dr. Jack Ogden to speak. He will provide an in-depth analysis of the evolution of jewellery craftsmanship and changes in aesthetic tastes across different eras.Over 20 forums on hot topics including AI and digital marketingMore than 20 seminars and networking sessions will be held, covering industry trends, digital marketing and jewellery technologies. A session will examine how artificial intelligence moves from design to commercialisation to drive the development of the jewellery industry. There will also be seminars where influencers share how to leverage e-commerce platforms to enhance jewellery brand visibility, boost sales, and share practical experience, to help the industry accelerate the integration and synergy between online and offline channels.Business opportunities and industry exchangeThe exhibition attracts major international jewellery retail chains, as well as high-end, affordable luxury, and designer jewellery brands from around the world for sourcing. It creates business opportunities for both buyers and sellers while fostering industry exchange.The HKTDC has partnered with the Hong Kong Tourism Board and local enterprises to provide exclusive buyer privileges. These offers include dining, air tickets, and hotels, enabling buyers to enjoy Hong Kong’s unique charm while attending the fairs. The HKTDC will arrange free shuttle bus services between AsiaWorld-Expo and urban areas (including the Hong Kong Convention and Exhibition Centre in Wan Chai). For details, please refer to the fair’s official website.Combining online and offline services to facilitate sourcingThe shows use the EXHIBITION+ hybrid format. In addition to on-site procurement, the HKTDC’s AI-powered “Click2Match” will provide online business-matching for exhibitors and buyers from 23 February to 13 March. On-site buyers can use "Scan2Match" to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. To ease the buyer admission process, the HKTDC Marketplace App and the official websites of the two shows provide online verification functions. Buyers need only register through these platforms and upload a photo and valid identification to obtain a verified eBadge for direct entry, greatly reducing queuing times for onsite registration and verification and enhancing sourcing efficiency.Photo download: https://bit.ly/4ayrcAoAttending the press conference to introduce the twin jewellery shows today (5 February): Jenny Koo, HKTDC Deputy Executive Director (centre), Winston Chow, Chairman, HKTDC Jewellery Advisory Committee (left) and Kent Wong, Chairman, HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem and Pearl Show Fair Organising Committee (right)Jenny Koo (front row, third left) took a group photo with members of the organising committee of the HKTDC Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem and Pearl Show, joined by celebrity guestArtist Hera Chan (third right) led a group of models to exhibit exquisite jewellery pieces from the showsArtist Hera Chan wore a natural Myanmar jadeite set presented by exhibitor On Tung Company. The exquisite ensemble featured a translucent emerald green jadeite and diamond necklace, ring, and earrings, showcasing a regal and graceful designThe phoenix features in traditional Chinese wedding jewellery, symbolizes auspiciousness and good fortune. Exhibitor Lao Feng Xiang Jewellery Hong Kong Limited presented a "China chic" wedding collection imbued with Oriental charm, crafting accessories that embody the imperial elegance of a royal court for womenWebsites Hong Kong International Jewellery ShowExhibition websitehttp://hkjewelleryshow.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcecActivity listhttps://www.hktdc.com/event/hkjewellery/tc/intelligence-hub Hong Kong International Diamond, Gem & Pearl ShowExhibition websitehttp://hkdgp.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-aweActivity listhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hubHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 亞太地區燃油供應服務商萬利集團（以下簡稱（「萬利」或（「集團」）於2月2日舉辦以「開拓新視野：以可持續燃料推動綠色航運」為主題的首屆環境、社會與治理（ESG）論壇。論壇匯聚航運高管、金融家、法律專家及冰川學家，共同探討應對航運業迫切減碳挑戰的方案。以下演講嘉賓陣容於論壇探討關鍵議題，分享獨特見解：萬利集團主席兼行政總裁謝威廉博士 萬利集團獨立董事、Chooi & Company合夥人、馬來西亞大律師公會前會長及LAWASIA執行委員會委員謝依玲女士國泰世華銀行資本市場暨顧問部協理劉名軒先生 極地探險家、冰川學家及政策顧問、Polar Research and Expedition Consultancy創辦人／冰川學家與遠征總監張偉賢博士 滙豐香港工商金融可持續金融高級經理張雯瑾女士是次論壇為思想領袖提供了一個互動及對話的平台，並透過演講嘉賓的專題講座探討若干關鍵議題，包括氣候變化對全球航運的影響、持續轉變的可持續發展相關法規，及創新綠色及可持續發展掛鈎融資解決方案。謝威廉博士在主題演講中表示：「全球航運業正處於關鍵時刻，迅速轉變的監管法規、緊張的地緣政治局勢、氣候挑戰及技術發展正以前所未有的速度重塑行業格局。因此，我們期望打造一個協作環境，讓持份者聚首一堂，分享見解並制定策略，以構建可持續未來。」在論壇上，謝依玲女士討論ESG如何成為保障地球健康的法律、經濟和道德必要條件，並強調政府、企業、法院及資本市場必須在全球層面上通力合作，將可持續發展願景轉化為可量化的實際行動。謝女士表示：「我們必須建立全球健康指標體系，以系統追踪環境影響、健康影響及風險對全人類的綜合作用。這不僅需要量化工具評估進展，更需制定戰略傳播方案以提升全球認知、推動全民教育。同時，必須將指標體系深度融入組織、國家及國際治理架構，在本土和全球層面同步實施。企業應踐行負責任的商業倫理，全面對標ESG準則，構建普適性的全球健康框架。唯有通過全球協同標準化，方能實現框架的系統化落地與長效運行。」劉名軒先生分享其對將ESG特徵融入融資策略的見解：「綠色貸款（Green Loans）在企業擁有明確、具體的投資計劃時尤其適合。可持續發展掛鈎貸款（Sustainability-Linked Loans，SLLs）遵循獨特的邏輯：其關鍵績效指標（KPIs）必須反映重大的可持續議題，並且可量化、追踪和獨立驗證。最重要的是，可持續性績效目標（Sustainability Performance Targets，SPTs）必須在『積極進取』和『實際可行』之間取得平衡，確保在公司的運營能力範圍內有機會實現目標。與綠色貸款不同，SLLs不限制所得款項只用於綠色活動上；相反，SLLs通過與績效掛鈎的金融機制展示可持續承諾。除了貸款和債券，幾乎所有負債型金融産品現在都可以加入綠色或可持續性元素。這種靈活性使得企業能夠將融資與可持續目標結合在一起，一方面保持運營的實際可行性，也能推動環境進步與金融創新。」張偉賢博士分享其對地球科學教育與倡導的堅定承諾，並探討航運業的負責任發展機遇：「航運行業的可持續發展機遇始於認識到北極不僅是一條捷徑，更是一個生機勃勃的家園和地球脆弱的氣候調節器。新開通的極地航綫雖能縮短運輸時間、降低燃油消耗，但其航經水域存在基礎設施匱乏、生態系統脆弱、原住民依賴海冰維繫文化與生存等挑戰。真正的領導力意味著要投資於更清潔的燃料、冰級船舶和強化搜救能力，同時嚴格限制黑碳排放（Black Carbon Reduction），並尊重國際極地法規。這也意味著傾聽在冰上安全旅行了數千年的地方知識，並將這種智慧與現代科學和衛星數據融合。如果行業將ESG原則嵌入到每一次北極航行中，這些新興航綫能夠成為可持續創新的典範，而非不受控制風險的新邊界。」張雯瑾女士從可持續金融角度分享航運業轉型趨勢：「監管不斷變化，應對氣候目標和實現可持續海洋運輸的策略亦需要與時並進。目前，創新方案也應運而生，船東群體正探索生物燃料、生物液化天然氣（bio-LNG）、生物沼氣等替代能源方案。清潔技術研發持續，有助推動全球航運業向可持續模式的系統性轉型。」論壇在與會人士熱烈交流中圓滿結束，除交流意見外，他們亦重申對推動航運業可持續發展的共同承諾。萬利集團在可持續發展領域的領導地位突出，顯示其在引領行業減碳與推行負責任實踐方面的不懈努力。集團亦透過參與EcoVadis永續性評級系統及支持多元化可持續船用燃料，持續推進航運業的有效轉型。展望未來，集團將繼續舉辦更多論壇，促進對話交流、創新及合作，從而建立更可持續的海洋生態系統。謝威廉博士補充：「以上不過是個開端，萬利將繼續為行業及客戶制定切實可行的減碳解決方案。」有關萬利集團及其可持續發展方案的更多訊息，請瀏覽 www.banle-intl.com。圖片說明1：謝威廉博士（中）向演講嘉賓及論壇成員致送紀念品以示感謝。圖片說明2：論壇成員就「開拓新視野：以可持續燃料推動綠色航運」主題進行討論。謝依玲女士（左）擔任主持人，引領討論並以論壇成員身份分享見解。圖片說明3 ：與會人士在 ESG 論壇上聚集，展現了對航運業可持續實踐和創新解決方案的共同承諾。關於萬利集團萬利集團成立於 2015 年，以CBL International Limited（納斯達克：BANL）在納斯達克股票市場上市。我們致力於為客戶提供一站式燃油供應服務，被業內稱為燃油供應服務商。我們主要通過當地實體供貨商為船舶提供燃油加注服務，遍布比利時、中國、香港、印度、日本、韓國、馬來西亞、毛里裘斯、巴拿馬、菲律賓、新加坡、台灣、泰國、土耳其和越南，共覆蓋65個港口。集團積極推動可持續燃料，並已取得ISCC EU和ISCC Plus認證，以及EcoVadis銀獎。如欲瞭解更多信息，請到集團網站 https://www.banle-intl.com 瀏覽。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Banle Group (“Banle” or the “Group”), a leading Asia-Pacific marine fuel logistics provider, hosted its landmark inaugural ESG Forum — "Charting the New Horizon: Powering Green Shipping with Sustainable Fuels" — uniting top maritime executives, financiers, legal experts, and climate scientists to address the shipping industry's urgent decarbonization challenges on February 2.Speaker Lineup Tackles Critical IssuesThe forum featured exclusive insights from:Dr. Teck Lim Chia, Chairman and CEO of Banle GroupMs. Karen Cheah Yee-Lynn, Independent Director of Banle Group, Partner of Chooi & Company, Immediate Past President of the Malaysian Bar and EXCO Member of LAWASIAMr.Matt Liu Ming-Hsuan, SVP Capital Solutions, Cathay United BankDr.Wilson Cheung Wai-yin, Polar Explorer, Glaciologist and Policy Advisor, Polar Research and Expedition ConsultancyMs.Rebecca Zhang, Senior Manager Sustainable Finance, Commercial Banking, Hong Kong, HSBCThe forum served as a dynamic platform for thought leadership and dialogue, featuring a series of presentations addressing critical topics such as the impact of climate change on global shipping, evolving sustainability-related regulations, and innovative green and sustainability-linked financing solutions.Dr.Teck Lim Chia addressed in the keynote speech, “The global shipping industry stands at a pivotal moment. Rapid regulatory changes, geopolitical tensions, climate challenges, and technological advancements are reshaping the landscape at unprecedented speed. Yet, we are dedicated to fostering a collaborative environment where stakeholders can come together to share insights and develop strategies for a more sustainable future.”On the forum, Ms.Karen Cheah talked about how ESG has become a legal, economic, and moral imperative to safeguard planetary health – and how governments, businesses, courts, and capital markets at an international level must work together holistically to turn sustainability from aspiration into measurable action. She said, “We must establish planetary health metrics to track environmental, health, and risk impacts on all of us. This requires not only a measurement to gauge our progress but also a strategic plan to communicate these metrics, drive global awareness, and educate society at large. Moreover, we must integrate these metrics into governance structures at organizational, domestic, national, and international levels. We must engage in responsible business practices aligned with ESG components and ensure a robust framework for planetary health is implemented globally. Once we align collectively, we can systemize this framework for lasting impact.”Mr.Matt Liu shared his insight on integrating ESG features into financing strategies, “Green loans excel when companies have a clear, specific investment plan. Sustainability-Linked Loans (SLLs) operate under a distinct logic: their Key Performance Indicators (KPIs) must reflect material sustainability issues, be measurable, traceable, and independently verifiable. Crucially, Sustainability Performance Targets (SPTs) must balance ambition with feasibility, remaining achievable within the company’s operational capacity. Unlike green loans, SLLs do not restrict proceeds to green activities; instead, they demonstrate sustainability commitment through performance-linked financial mechanisms. Beyond loans and bonds, nearly all liability-style financial products can now integrate green or sustainability elements. This flexibility allows companies to align financing with sustainability goals while maintaining operational practicality, driving both environmental progress and financial innovation.”Dr.Wilson Cheung addressed his dedication to geoscientific education and advocacy, and talked about the responsible opportunities for the shipping industry, “Responsible opportunities in the shipping industry begin with recognising that the Arctic is not only a shortcut, but also a living homeland and a fragile climate regulator for the planet. New polar sea routes can reduce transit time and fuel use, yet they cross waters where infrastructure is scarce, ecosystems are vulnerable, and Indigenous communities depend on sea ice for culture and survival. True leadership means investing in cleaner fuels, ice-class vessels, and robust search-and-rescue capacity, while strictly limiting black carbon emissions and respecting international polar regulations. It also means listening to local knowledge that has guided safe travel on ice for thousands of years and integrating that wisdom with modern science and satellite data. If the industry embeds ESG principles into every Arctic voyage, these emerging routes can become a model of responsible innovation rather than a new frontier of unchecked risk.”Ms.Rebecca Zhang shared recent shipping industry transition trends from a sustainable finance perspective: “Regulations are constantly evolving, and so must global efforts to tackle climate change and make maritime transport more sustainable. Innovative solutions are emerging, and shipowners are exploring alternative energy options such as biofuels, bio-LNG, and bio-gas. The development of clean technologies is accelerating the industry’s systemic shift towards sustainability.”The forum concluded with a lively and interactive networking among participants, who exchanged ideas and reaffirmed their collective commitment to advancing sustainable practices throughout the shipping industry.Banle Group's sustainability leadership by example through its operational practices was prominently showcased, highlighting its ongoing efforts to spearhead industry decarbonization and responsible practices. Through initiatives like its participation in the EcoVadis rating system and advocacy for diverse sustainable marine fuels, Banle continues to drive meaningful transformation across the shipping sector.Looking ahead, the Banle Group remains committed to hosting future forums that foster dialogue, innovation, and collaboration for a more sustainable maritime ecosystem.Dr.Teck Lim Chia added: "This is just the beginning. Banle will continue driving practical decarbonization solutions for our industry and clients."For more information about Banle Group and its sustainability initiatives, please visit www.banle-intl.com.Photo Caption 1: Dr. Teck Lim Chia (centre) presented souvenirs to all speakers and panelists as a token of appreciation.Photo Caption 2: Panelists engaged in a discussion on the theme: “Charting the New Horizon: Powering Green Shipping with Sustainable Fuels”. Ms. Karen Cheah (left) served as moderator, guiding the discussion while also contributing her insights as a panelist.Photo caption 3: Attendees gathered at the ESG Forum, showcasing a shared commitment to sustainable practices and innovative solutions in the shipping industry.About Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information, please visit: https://www.banle-intl.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - Annature, Australia's leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.The new capability ensures Annature customers can meet the U.S. Food and Drug Administration's requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap."As we continue to grow globally, it's critical that Annature supports the regulatory frameworks our customers operate under," said Corey Cacic, CEO of Annature. "Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards."The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.Kim Steel, Founder and Managing Director of SAPRO - a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release."For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional - it is fundamental," said Steel. "It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times."The launch further strengthens Annature's position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.About AnnatureAnnature is Australia's leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature's growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.https://www.annature.com.auCONTACT:Name: Corey CacicEmail: corey@annature.com.auSOURCE: Annature Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MORTSEL, BE, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.Best in KLAS® - Enterprise Imaging (United States)Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small - under 300k studies) segment.XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive yearEnterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year."Being recognized across three Enterprise Imaging segments - including multiple consecutive wins - is a powerful affirmation of our clinician-first strategy," said Nathalie McCaughley, President of AGFA HealthCare. "Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging."Commenting on the awards, Adam Gale, CEO of KLAS Research, said:"The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come."Monique Rasband, Global Vice President of Imaging at KLAS Research, added:"AGFA HealthCare's strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation."The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.KLAS referencesBest in KLAS Awards overview: 2026 Best in KLAS Awards: Software and Services ReportEnterprise Imaging segments reports: 2026 Best in KLAS Awards: Software and Services ReportAbout AGFA HealthCareAt AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That's why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one's thought process, and each clinician has everything they need to perform at the top of their craft. That's life in flow.This belief shapes everything we do - guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.About KLAS ResearchKLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.Best in KLAS® is a registered trademark of KLAS Research.Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.comSOURCE: Agfa HealthCare Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

上海, 2026年2月5日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK，以下簡稱「公司」），一家專注於創新藥研發、臨床開發、制造及商業化的生物制藥公司，今日宣布與陝西麥科奧特醫藥科技股份有限公司（以下簡稱「麥科奧特」）簽署獨家商業化許可協議，獲得MT1013在中國及亞太區（日本除外）的獨家商業化授權。MT1013為全球首創的雙靶點受體激動劑多肽，可同時靶向鈣敏感受體(CaSR)及成骨生長肽(OGP)受體，開發主要用於治療繼發性甲狀旁腺功能亢進症(SHPT)。此次戰略合作將與雲頂新耀現有腎科管線形成協同效應，強化產品佈局，鞏固公司在亞洲腎髒及自身免疫疾病領域的領導地位，並將產品覆蓋從IgA腎病拓展至更廣泛的慢性腎髒病領域。根據協議，雲頂新耀將向麥科奧特支付人民幣2億元首付款，以及最高不超過人民幣10.40億元的潛在監管及商業里程碑付款。中國III期臨床研究正在進行中，相關臨床開發費用將由麥科奧特承擔。MT1013是由麥科奧特自主研發的全球首創雙靶點多肽新藥，2025年獲美國腎髒病學會（ASN）年會「Late-Breaking」收錄。其開創性地融合了「鈣敏感受體（CaSR）+成骨生長肽（OGP）模擬」雙重作用機制，解決了PTH、鈣、磷代謝平衡的問題，這一全新設計使其在治療繼發性甲狀旁腺功能亢進（SHPT）及相關骨代謝疾病時，首次創造性的從源頭上控制病情，且能通過直接激活成骨通路，主動促進骨形成與修複，實現從「間接抑制骨吸收」到「主動促進骨生成」的治療創新升級。臨床研究證實，MT1013在慢性腎病接受維持性血液透析伴繼發性甲狀旁腺功能亢進患者中，起效迅速、效力強且持久，安全性良好，在綜合達標率（iPTH, 血鈣，血磷均達標）、血鈣鈣化指標的控制及心血管獲益前景上均展示出超越現有療法的潛力。目前，MT1013正在中國開展針對該患者群體的III期臨床研究，已入組超50%。SHPT是慢性腎髒病（CKD）患者最常見的嚴重並發症之一。該疾病導致鈣磷代謝紊亂、甲狀旁腺激素升高、骨病變、血管鈣化等一系列病理變化，顯著增加骨折、心血管事件和死亡風險，是影響CKD患者預後的關鍵因素。隨著全球慢性腎髒病患者規模持續擴大，SHPT及其相關治療需求亦不斷增長。數據顯示，全球CKD患者人數已由2019年的9.052億人增至2024年的10.655億人，預計2030年將超12億人，2035年將超15億人；同期全球SHPT患者人數亦持續增長，預計2030年將達約1.899億人，2035年將達約2.217億人，臨床需求亟待滿足。雲頂新耀董事會主席吳以芳表示：「我們非常高興能與麥科奧特達成此次合作。在全球慢性腎髒病患者持續增加的背景下，繼發性甲狀旁腺功能亢進仍存在顯著臨床未滿足需求。MT1013作為具備全球首創雙重作用機制的臨床後期創新資產，有望為SHPT患者提供全新的治療選擇。作為潛在同類最佳藥物，MT1013將與公司現有的腎科產品組合形成高度協同，進一步夯實公司在腎科領域的佈局。雲頂新耀在持續深耕自身免疫相關腎髒疾病的基礎上，正加速拓展至腎小球腎炎以及慢性腎髒病及其並發症等更廣泛的治療領域。此次合作是公司完善創新管線、拓展腎科治療邊界的重要戰略舉措，標志著腎科戰略由聚焦單一疾病領域向系統化和平台化的發展階段升級。未來，雙方將協同推進MT1013的開發與商業化，為更廣泛的腎病患者提供創新治療選擇。」麥科奧特創始人、董事長王冰博士表示：「我們很高興與雲頂新耀達成此次戰略合作。雲頂新耀在腎病領域擁有深厚的市場積累和成熟的商業化體系，是推動MT1013惠及中國乃至全球患者的理想合作夥伴。MT1013是公司多肽技術平台的重要成果，代表著公司在慢病創新治療領域深耕的重要里程碑達成，其獨特的雙靶點機制有望為SHPT治療帶來突破和更多獲益。我們期待與雲頂新耀緊密協作，加速該產品的臨床開發和上市進程，共同滿足廣大未滿足的臨床需求，開啟腎病領域治療的全新篇章。」MT1013已完成關鍵II期臨床研究，數據顯示，MT1013在維持性血液透析伴SHPT患者中，展現出強效且持久的iPTH抑制能力，並在與依特卡肽頭對頭比較中實現了綜合管理的優勢——其iPTH、血鈣、血磷三項同時達標率更高，降磷及降低心血管風險標志物FGF-23的優勢更強，加之MT1013在長達52周的治療中也為患者人群帶來了顯著的骨密度提升及骨代謝標志物改善，逐步驗證了其獨特的雙重機制在SHPT患者中綜合管理及改善骨骼健康方面的潛在臨床獲益。目前MT1013已進入以西那卡塞為陽性對照的確證性III期臨床試驗。該III期試驗已在全國範圍內啟動超過100家研究中心，計劃招募約424名患者，主要針對慢性腎髒病維持性血液透析伴 SHPT的患者群體。關於MT1013MT1013為全球首創的雙靶點受體激動劑多肽，可同時靶向鈣敏感受體（CaSR）及成骨生長肽（OGP）受體，開發主要用於治療繼發性甲狀旁腺功能亢進症（SHPT），並計劃拓展至包括慢性腎病性礦物質和骨代謝異常（CKD-MBD）伴骨質疏松及未接受透析的SHPT在內的額外適應症。MT1013已於2025年5月完成針對SHPT的II期臨床研究（MT1013-II-C01），並已進入以西那卡塞為對照的III期臨床研究。關於雲頂新耀雲頂新耀是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先制藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並嚴格按照國家藥品監督管理局（NMPA）和歐洲藥品管理局（EMA）的 GMP 要求及世界衛生組織（WHO）PQ 標准建設。公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎髒及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命周期商業化能力於一體的商業化平台，並以擁有全球權益的自研 mRNA 平台為基礎，持續推進mRNA in vivo CAR-T 與 mRNA 腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。關於麥科奧特陝西麥科奧特醫藥科技股份有限公司（以下簡稱「麥科奧特」）於2007年1月在西安成立，現已完成西安、蘇州、北京、上海、中國香港、美國佈局。公司是一家專注於新藥研發的創新型醫藥科技企業，致力於成為雙功能和多功能特異性多肽藥物研發的領軍性前沿企業，聚焦於心腦血管、代謝類疾病相關領域的新藥研發。公司是是雙特異性多肽概念的提出者、實施者、驗證者和開發者，是多肽類藥物研發的優秀平台之一，具有篩選多靶點多肽藥物的特殊機制，具備開發First-in-class和Best-in-class品種的平台型研發能力，現已儲備多個新藥品種，其中進入臨床研發的有7個原研創新藥管線，包括1個臨床三期階段，3個臨床二期階段，3個臨床一期階段。公司致力於創制新藥、挽救生命，滿足未被滿足的臨床需求，用科技創新為人類健康保駕護航。更多信息，請訪問公司官網：www.micot.cn。前瞻性聲明本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com